Lutris Pharma Receives Notice of Allowance for Key U.S. Patent Application Covering Lead Compound, LUT014, a Novel B-Raf Inhibitor
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects,...